Suppr超能文献

使用稳定的阿霉素-碘油混悬液评估原发性肝癌的化疗栓塞治疗。

Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin-lipiodol suspension.

作者信息

Horiguchi Y, Itoh M, Takagawa H, Imai H, Kamei A, Sekoguchi B, Nagamura Y

机构信息

Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan.

出版信息

Cancer Chemother Pharmacol. 1992;31 Suppl:S60-4. doi: 10.1007/BF00687107.

Abstract

We formulated a new lipiodol-Adriamycin suspension (ADM/lipiodol, 50 mg/10 ml) that remained stable for 48 h (half-life, 25 +/- 3 days). In five cases of hepatocellular carcinoma (HCC) resected after intra-arterial infusion of this agent, the ADM concentration in the tumor was quite high and the tumor necrosis rate was more than 80% on histological examination. Over a 5-year period, 180 patients with unresectable HCC underwent transcatheter arterial embolization therapy (TAE) in the presence or absence of this agent. The regimens consisted of suspension injection alone (A, n = 54), suspension injection + TAE using gelatin sponge (B, n = 29), TAE followed by suspension injection (C, n = 34), and TAE alone (D, n = 63). The estimated 1-year survival values determined for patients treated with these regimens were 70%, 73%, 43%, and 39% respectively, and the corresponding 3-year survival values were 27%, 31%, 15%, and 10%. The survival achieved using suspension injection was thus superior to that obtained using conventional TAE, and combined therapy with suspension injection followed by TAE seemed to enhance survival, although there were some biases in tumor size and in the stage of tumor progression. For patients with tumors measuring 5 cm or more in diameter, the survival obtained using regimen A was lower than that achieved using regimen D, but the combination of TAE and suspension injection improved the 1-year survival value obtained using regimen D from 34% to 52%. For patients with tumors measuring less than 5 cm in diameter, the survival achieved using regimen A was markedly better than that obtained using regimen D, although no difference was found between the survival value achieved using regimen A and that obtained using regimens B and C. On the basis of these results, our newly formulated ADM-lipiodol suspension was surmised to be effective by itself against relatively small HCC tumors, whereas it enhanced the efficacy of conventional TAE in large lesions.

摘要

我们配制了一种新的碘油-阿霉素混悬液(阿霉素/碘油,50毫克/10毫升),其在48小时内保持稳定(半衰期,25±3天)。在5例经动脉内注入该制剂后接受肝细胞癌(HCC)切除术的患者中,肿瘤内阿霉素浓度相当高,组织学检查显示肿瘤坏死率超过80%。在5年期间,180例无法切除的HCC患者接受了经导管动脉栓塞治疗(TAE),治疗时使用或不使用该制剂。治疗方案包括单纯混悬液注射(A组,n = 54)、混悬液注射+使用明胶海绵的TAE(B组,n = 29)、TAE后进行混悬液注射(C组,n = 34)以及单纯TAE(D组,n = 63)。用这些方案治疗的患者的估计1年生存率分别为70%、73%、43%和39%,相应的3年生存率分别为27%、31%、15%和10%。因此,使用混悬液注射获得的生存率优于使用传统TAE获得的生存率,尽管在肿瘤大小和肿瘤进展阶段存在一些偏差,但混悬液注射后再进行TAE的联合治疗似乎提高了生存率。对于直径5厘米或更大的肿瘤患者,使用方案A获得的生存率低于使用方案D获得的生存率,但TAE与混悬液注射的联合将使用方案D获得的1年生存率从34%提高到了52%。对于直径小于5厘米的肿瘤患者,使用方案A获得的生存率明显优于使用方案D获得的生存率,尽管使用方案A获得的生存率与使用方案B和C获得的生存率之间没有差异。基于这些结果,推测我们新配制的阿霉素-碘油混悬液本身对相对较小的HCC肿瘤有效,而在大病灶中它增强了传统TAE的疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验